Evidence map›Paper›PMID 32194702›Full record

ArticleOncology letters2020

Downregulation of extracellular vesicle microRNA-101 derived from bone marrow mesenchymal stromal cells in myelodysplastic syndrome with disease progression.

Yuu Saitoh, Tomohiro Umezu, Satoshi Imanishi, Michiyo Asano, Seiichiro Yoshizawa, Seiichiro Katagiri, Tamiko Suguro, Hiroaki Fujimoto, Daigo Akahane, Chiaki Kobayashi-Kawana and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Extracellular Vesicles in Myeloid Neoplasms.International journal of molecular sciences · 2022
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Yuu SaitohDepartment of Hematology, Tokyo Medical University, Tokyo 160-8402, Japan.
Tomohiro UmezuDepartment of Hematology, Tokyo Medical University, Tokyo 160-8402, Japan.
Satoshi ImanishiInstitute of Medical Sciences, Tokyo Medical University, Tokyo 160-0023, Japan.
Michiyo AsanoDepartment of Hematology, Tokyo Medical University, Tokyo 160-8402, Japan.
Seiichiro YoshizawaDepartment of Hematology, Tokyo Medical University, Tokyo 160-8402, Japan.
Seiichiro KatagiriDepartment of Hematology, Tokyo Medical University, Tokyo 160-8402, Japan.
Tamiko SuguroDepartment of Hematology, Tokyo Medical University, Tokyo 160-8402, Japan.
Hiroaki FujimotoDepartment of Hematology, Tokyo Medical University, Tokyo 160-8402, Japan.
Daigo AkahaneDepartment of Hematology, Tokyo Medical University, Tokyo 160-8402, Japan.
Chiaki Kobayashi-KawanaDepartment of Hematology, Tokyo Medical University, Tokyo 160-8402, Japan.
Junko H OhyashikiInstitute of Medical Sciences, Tokyo Medical University, Tokyo 160-0023, Japan.
Kazuma OhyashikiDepartment of Hematology, Tokyo Medical University, Tokyo 160-8402, Japan.
Tokyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To evaluate the mechanism underlying the communication between myeloid malignant and bone marrow (BM) microenvironment cells in disease progression, the current study established BM mesenchymal stromal cells (MSCs) and assessed extracellular vesicle (EV) microRNA (miR) expression in 22 patients with myelodysplastic syndrome (MDS) and 7 patients with acute myeloid leukemia and myelodysplasia-related changes (AML/MRC). Patients with MDS were separated into two categories based on the revised International Prognostic Scoring System (IPSS-R), and EV-miR expression in BM-MSCs was evaluated using a TaqMan low-density array. The selected miRs were evaluated using reverse transcription-quantitative PCR. The current study demonstrated that the expression of BM-MSC-derived EV-miR was heterogenous and based on MDS severity, the expression of EV-miR-101 was lower in high-risk group and patients with AML/MRC compared with the control and low-risk groups. This reversibly correlated with BM blast percentage, with which the cellular miR-101 from BM-MSCs or serum EV-miR-101 expression exhibited no association. Database analyses indicated that miR-101 negatively regulated cell proliferation and epigenetic gene expression. The downregulation of BM-MSC-derived EV-miR-101 may be associated with cell-to-cell communication and may accelerate the malignant process in MDS cells.

Indexed as

bone marrow mesenchymal stroma cellsdisease progressionextracellular vesiclemicroRNA-101myelodysplastic syndrome

Identifiers

PMID32194702
PMCPMC7038917
OpenAlexW2998767563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.